Background
==========

Liver transplantation (LT) is the standard therapy for end-stage liver diseases \[[@b1-anntransplant-25-e921529]\]. However, there is an urgent need to increase the number of livers for transplantation, due to the high waiting-list mortality \[[@b2-anntransplant-25-e921529]\]. To enlarge the donor organ pool, extended-criteria donor (ECD) grafts, such as livers from donation after circulatory death, as well as elderly and steatotic grafts, are more frequently used \[[@b3-anntransplant-25-e921529]\]. The use of ECD livers is associated with higher risks of post-transplant complications, such as early allograft dysfunction (EAD), primary nonfunction (PNF), and cholangiopathies \[[@b4-anntransplant-25-e921529],[@b5-anntransplant-25-e921529]\]. To effectively make use of ECD livers, a better preservation method is required, along with the ability to assess graft viability and repair graft injuries.

Recently, *ex vivo* normothermic machine perfusion (NMP) as a preservation method has attracted great attention \[[@b6-anntransplant-25-e921529]\]. The novel preservation technique can provide nutrition and oxygen to the livers at a physiological temperature. NMP can maintain metabolic activity and remove the harmful substances caused by ischemic injuries of grafts \[[@b7-anntransplant-25-e921529]\]. A number of animal experiments and clinical trials have shown that NMP is superior to cold storage in protection of liver grafts \[[@b8-anntransplant-25-e921529]--[@b13-anntransplant-25-e921529]\].

The national deceased organ donation system has been established in China since January 2015. There are 3 categories of organ donation, including donation after brain death (DBD), donation after circulatory death (DCD), and Organ Donation after Brain Death followed by Circulatory Death (DBCD) \[[@b14-anntransplant-25-e921529]\]. Due to having less experience in maintenance techniques of potential donors, the incidence of EAD is 55.91%, which is higher in China than the incidence (23%) in the United States \[[@b15-anntransplant-25-e921529],[@b16-anntransplant-25-e921529]\]. In this circumstance, NMP might provide a better method than cold storage to preserve donor livers in China. Herein, we reported the first series of ECD liver transplantations using NMP preservation.

Case Reports
============

Donor livers
------------

This study retrospectively analyzed the first 4 ECD livers with NMP preservation in the First Affiliated Hospital of Sun Yat-sen University. The transplants were performed between September 2018 and March 2019. The definition of warm ischemia time (WIT) was from cardiac arrest to *in situ* cold perfusion. The 4 liver grafts defined as ECD were respectively satisfied with DCD, DCD with peak serum natrium \>165 mmol/L, DCD with poor *in situ* perfusion, and DBD with serum total bilirubin \>3 mg/dL \[[@b17-anntransplant-25-e921529]\].

Four liver grafts were procured in 3 organ procurement organizations in Guangdong Province. Ice-cold University of Wisconsin (UW) solution was flushed *in situ* into the superior mesenteric vein and abdominal aorta. At this time, the color of the liver and the effluent from the inferior vena cava were observed, and the texture of the liver was felt to judge whether the liver was adequately and uniformly perfused.

Once it arrived at our center, each liver was assessed by an experienced transplant surgeon. The first liver graft was from a DCD donor, with a WIT of 22 min. The recipient suffered from acute liver failure (ALF). For patient safety, NMP was used to preserve the donor liver. The second liver graft was also from a DCD donor, with a WIT of 10 min, accompanied with a very high sodium level (173.3 mmol/L). The third liver felt hard to the touch and the graft appearance was not normal because of poor *in situ* cold perfusion. Moreover, it was also a DCD liver. Therefore, it was considered for NMP preservation. The fourth liver had a high serum total bilirubin level (141.5 umol/L) before procurement. To ensure the recipient's safety, we used NMP to assess the viability of the graft.

Normothermic machine perfusion
------------------------------

The NMP device (Liver Assist, Groningen, The Netherlands) consists of a rotary pump, oxygenator, heat exchanger, connecting pipeline and other components. Two rotary pumps provide a pulsatile flow to the hepatic artery (HA) and a continuous flow to the portal vein (PV). The system is pressure and temperature controlled. Pressure was set at 50 mmHg in the hepatic artery and 11 mmHg in the portal vein. The perfusate was warmed to 37°C before perfusion \[[@b18-anntransplant-25-e921529]\]. The perfusate consisted of 6 units of leucocyte-depleted washed red blood cells, 0.6 L succinylated gelatin, 100 mL sodium bicarbonate, 37500 units heparin, 2 g Imipenem and Cilastatin Sodium (Pfizer, USA), 20 ml calcium chloride, 3 ml magnesium sulphate and 125 ml amino acid. The flow, pressure and temperature are displayed on the device in real time, and are recorded every 20 min. Blood gas of perfusate was measured every 10 min for the first 40 min, and then every 20 min. The oxygen flow was controlled through an oxygenator supplied with a mixture of O~2~ and air, with the aimed perfusate PaO~2~ of 200 mmHg. According to the results of blood gas analysis of perfusate, oxygen supply concentration/flow and perfusion fluid composition can be adjusted over time. Bile was collected from the biliary draining tube and the volume was measured every hour. Bile was collected hourly and was also subjected to blood gas analysis. Machine perfusion was maintained until the recipient's liver was removed. Liver graft viability was assessed by the following criteria: the perfusate lactate level was below 2.5 mmol/L within 4 h of perfusion, the liver had to produce bile, stable artery flow was more than 150 ml/min and portal venous flow was more than 500 ml/min, and perfusate pH was greater than 7.3 \[[@b19-anntransplant-25-e921529]\]. The liver graft was flushed with 2 L of cold saline. Vascular and bile duct cannulas were removed, and liver biopsies were taken at the end of perfusion. The graft was immediately implanted and reperfused in the standard manner.

Transplant recipients
---------------------

The recipients were patients listed for liver transplantation at the First Affiliated Hospital of Sun Yat-sen University, China. All patients received an explanation about the principles of NMP while obtaining informed consent for liver transplantation. When an extended-criteria liver graft was available, the consultant surgeon re-explained the procedures in detail and obtained additional patient consent to accept the graft. The NMP proceeded only when the patient fully understood and accepted the possible risks and benefits. Informed consent was obtained from every patient. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University.

After surgery, the recipients were transferred to the Intensive Care Unit (ICU) for post-transplant care, including respiratory and circulatory support therapy, and liver function monitoring. Liver and coagulation function indicators were measured every day for the first 7 days after the operation. The duration of ICU and hospital stays were recorded. Postoperative complications such as biliary complications and early allograft dysfunction (EAD) were also documented. EAD was defined as satisfying any of the following characteristics: serum total bilirubin (Tbil) \>10 mg/dL on day 7 after the operation (excluding biliary stricture), serum international standardized ratio (INR) \>1.6 on day 7 after the operation, the peak level of serum glutamic oxaloacetic transaminase aspartate aminotransferase (AST) within the first 7 days after the operation was \> 2000 IU/L, and the peak level of serum alanine aminotransferase (ALT) within the first 7 days after the operation was \>2000 IU/L \[[@b20-anntransplant-25-e921529]\]. After discharge from the hospital, the patients were followed up in the outpatient clinic monthly for the first year.

Histology
---------

Biopsies were obtained from donor livers at 3 time points: before NMP, after NMP, and after reperfusion. Paraffin-embedded slides of liver biopsies were prepared for hematoxylin and eosin (HE) staining. Liver biopsies were assessed for sinusoidal congestion, hepatocyte necrosis and ballooning degeneration, based on the Suzuki criteria \[[@b21-anntransplant-25-e921529]\]. All samples were examined by an experienced liver pathologist.

Donor characteristics
---------------------

In total, 4 ECD livers were procured, successfully preserved using NMP and transplanted. None of the donors had history of hepatitis B infection. The median donor age was 21 (19--26) years. Three grafts were from DCD donors and 1 was from a DBD donor. The detailed donor characteristics are summarized in [Table 1](#t1-anntransplant-25-e921529){ref-type="table"}. Donor 1 was admitted with cerebral ischemia, having normal liver function. Donor 2 suffered from brain injury due to intracranial hemorrhage. Donor 3 was a 26-year-old male with a diagnosis of intracranial hemorrhage and a BMI of 17.86 kg/m^2^. Donor 4 was a 19-year-old female admitted with head trauma.

Perfusion characteristics
-------------------------

The median cold ischemia time (CIT) was 479.5 (334--638) min in this series. Prior to NMP, all liver grafts were flushed with 3 L of warm saline. There were no technical complications during NMP. The livers before and during perfusion are shown in [Figure 1](#f1-anntransplant-25-e921529){ref-type="fig"} (pictures of liver 4 were not available). All livers were ruddy and softer after perfusion.

Median NMP time was 310 (260--380) min ([Table 1](#t1-anntransplant-25-e921529){ref-type="table"}). The initial hemoglobin concentration was 54 (50--58) g/L and the final hemoglobin concentration was 51 (47--54) g/L. The HA flows were variable between livers, but along with perfusion, they gradually tended to be stable ([Figure 2A](#f2-anntransplant-25-e921529){ref-type="fig"}). The median of HA flow was 247.5 (201--310) mL/min at 1 h after perfusion. The HA flow in liver 1 was higher than in livers 2, 3, and 4. PV blood flow showed a slight upward trend, with a median arterial flow of 1010 (900--1160) mL/min at the end of perfusion ([Figure 2B](#f2-anntransplant-25-e921529){ref-type="fig"}).

After 1 h of perfusion, the pH value reached a relatively stable level, with a median value of 7.39 (range 7.37--7.44) ([Figure 2C](#f2-anntransplant-25-e921529){ref-type="fig"}). The glucose levels of perfusate of livers 2 and 3 were steady during the whole perfusion process, but increased rapidly at the beginning of perfusion in livers 1 and 4, and finally stabilized at 27.8 and 16.9 mmol/L, respectively ([Figure 2D](#f2-anntransplant-25-e921529){ref-type="fig"}). At the beginning of perfusion, lactate concentrations in perfusate were as high as 7.9 (5.2--8.7) mmol/L, but finally decreased to normal level, reflecting active metabolism of the livers ([Figure 2E](#f2-anntransplant-25-e921529){ref-type="fig"}).

Bile production was observed throughout the entire perfusion period ([Figure 3E](#f3-anntransplant-25-e921529){ref-type="fig"}). The median bile production after the first hour was 1.7 (1.0--2.0) mL ([Figure 3D](#f3-anntransplant-25-e921529){ref-type="fig"}). There was a gradual change in color to a darker shade ([Figure 3E](#f3-anntransplant-25-e921529){ref-type="fig"}). During perfusion, the pH values of bile produced by the 4 livers were quite different in the beginning, but at the end of perfusion, they were all around 8 (7.995, 7.915--8.011) ([Figure 3A](#f3-anntransplant-25-e921529){ref-type="fig"}). The concentration of bicarbonate increased, but it fluctuated in the bile produced by liver 1. The glucose concentration in bile continued to decrease ([Figure 3C](#f3-anntransplant-25-e921529){ref-type="fig"}). This was particularly evident in the bile of liver 1 ([Figure 3A](#f3-anntransplant-25-e921529){ref-type="fig"}), with a level of 18.2 mmol/L at the beginning to 8.4 mmol/L at the end.

As liver biopsies were taken from liver 1 and 2, histological examination of HE staining liver biopsies (×100) showed that there was no significant difference between biopsies taken before and after NMP and after reperfusion ([Figure 4](#f4-anntransplant-25-e921529){ref-type="fig"}). Liver 1 showed no signs of sinusoidal damage and hepatocyte necrosis. Mild ballooning degeneration was present after machine perfusion and after reperfusion. In contrast, liver 2 presented no obvious change in sinusoidal damage, hepatocyte necrosis, and ballooning degeneration after machine perfusion and after reperfusion.

Post-transplant outcomes and liver graft function
-------------------------------------------------

Recipient characteristics, transplant indications, and MELD scores are shown in [Table 1](#t1-anntransplant-25-e921529){ref-type="table"}. All recipients had a history of hepatitis B infection. One of them underwent liver transplantation for acute liver failure and the other 3 for cirrhosis. The median operation duration was 370 (350--405) min, and the median anhepatic phase was 34 (25--38) min. The median ICU stay was 48 (23--85) h, and the median length of hospital stay was 26 (17--29) days. In addition, recipient 1 in the study experienced postreperfusion syndrome (PRS), which was diagnosed by a decrease of 33% in mean arterial pressure (MAP) after anhepatic phase for 5 min with the use of norepinephrine (0.2 ug/kg/min) within the first 5 min after reperfusion.

The results of postoperative liver function tests are shown in [Figure 5](#f5-anntransplant-25-e921529){ref-type="fig"}. The serum ALT and AST levels decreased during the first week after transplantation, and values were nearly normal at 30 days after transplantation. The Tbil in recipients 2, 3, 4 initially increased to a temporary peak within 1 week after surgery, and then rapidly decreased to normal levels. The Tbil level of recipient 1 decreased continuously during the first 60 days after the operation. Serum glutamyltransferase (GGT) and alkaline phosphatase (ALP) levels tended to increase at first and then decreased after the operation. At 60 days after surgery, the serum GGT levels of recipients 1, 2, and 4 almost fell to normal levels, but the ALP concentrations were still higher than the normal range in all recipients. The INR was a little higher than the upper limit, but it decreased rapidly within 3 days. Due to their liver functions after transplant, no patients were diagnosed as PFN. The peak value of AST was 2106 U/L during the first 7 days after transplant for recipient 2, meeting the diagnostic criteria of EAD. At day 90 after transplantation, the liver enzymes and Tbil of recipient 1 increased significantly, which was confirmed by imaging studies as anastomostic biliary stricture. The stricture was cured by biliary stent placement. To date, no other biliary complications have occurred.

Discussion
==========

In this study, we successfully transplanted 4 ECD livers for recipients with end-stage liver disease after *ex situ* preservation and assessment using NMP. The results from short-term follow-up suggest the efficacy and safety of NMP in ECD liver transplantation in China.

Although great advancements have been made in organ transplantation in recent decades, the organ donor shortage is a severe problem all over the world \[[@b22-anntransplant-25-e921529]\], and high-risk donor livers are increasingly used in clinical settings. It is difficult for surgeons to decide whether to use an ECD liver for transplantation or to discard it due to an expected high risk of PNF, based on surgeon experience \[[@b23-anntransplant-25-e921529]\]. Fortunately, advances have been made in machine perfusion (MP) technology, including hypothermic machine perfusion (HMP), hypothermic oxygenated perfusion (HOPE), subnormothermic machine perfusion (SNMP), and NMP \[[@b11-anntransplant-25-e921529],[@b24-anntransplant-25-e921529]--[@b26-anntransplant-25-e921529]\]. HMP of kidneys can reduce the incidence of delayed graft function (DGF) in renal transplantation \[[@b27-anntransplant-25-e921529]\]. HMP is also feasible and effective to preserve high-risk liver grafts \[[@b28-anntransplant-25-e921529]\]. However, it is controversial whether HMP can improve graft survival \[[@b29-anntransplant-25-e921529]\]. In contrast to HMP, HOPE can ensure a supply of dissolved oxygen to liver grafts, and it minimizes preservation injury and replenishes adenosine triphosphate (ATP) stores to improve organ viability \[[@b30-anntransplant-25-e921529]\]. For SNMP, the rate of metabolism of liver graft can increase to close to 70% of the normal rate. Among these methods, only NMP can provide normothermic oxygenated blood supply to the organs, creating an environment close to physiological conditions, which enables the method to repair the injuries and also assess graft viability \[[@b6-anntransplant-25-e921529]\]. However, the NMP technology is more complicated and expensive. Therefore, the choice of machine perfusion technique needs to be based on the quality of organs, cost-effectiveness analysis, and technology availability.

Skaro et al. reported that livers from DCD had 2.1 times greater risk of graft failure, and 3.2 times greater risk of re-transplantation, compared with DBD recipients. In addition, DCD recipients have a 31.6% higher incidence of biliary complications and a 35.8% higher incidence of ischemic cholangiopathy \[[@b31-anntransplant-25-e921529]\]. In this study, the liver grafts from DCD were subjected to 22-min WIT and were transplanted successfully. As reported, grafts from DCD donors with 20--30 min WIT were defined as intermediate-risk ECD grafts \[[@b32-anntransplant-25-e921529]\]. Since the first recipient suffered from acute liver failure, the liver underwent NMP for safety. The recovery was uneventful, but an anastomotic stricture of the extrahepatic bile duct occurred at 3 months after transplantation. The second donor liver was subjected to 10-min WIT and hypernatremia. It has been shown that donor serum sodium level is correlated with liver transaminase level after transplant \[[@b33-anntransplant-25-e921529]\]. Figueras et al. reported that serum sodium levels \>155 mmol/L in donors was associated with higher incidences of liver re-transplantation and graft loss within 1 month after transplantation \[[@b34-anntransplant-25-e921529]\]. As a consequence, we considered NMP for this organ. Despite the presence of EAD (due to the peak AST level of 2106 U/L), the recipient is without complications to date. The third donor liver was subjected to insufficient cold perfusion during procurement with 6-min WIT. Insufficient cold perfusion can result in microthrombus, which increases the risk of graft failure. Before machine perfusion, the donor liver felt hard to the touch and the color was abnormal; we therefore used NMP preservation for this organ. The fourth donor had high serum bilirubin levels. High bilirubin in blood indicates that metabolic function of the donor liver is insufficient, and a donor with high serum bilirubin has elevated risk of graft failure after transplantation \[[@b35-anntransplant-25-e921529]\]. Thus, we attempted to use NMP to resuscitate it. To date, there have been no complications in the recipients of livers from donors 3 and 4.

NMP appears to have excellent potential as a technique to predict the viability and suitability of ECD organs. In the majority of cases, donor characteristics and gross surface appearance are used to decide to either use or discard donor livers \[[@b36-anntransplant-25-e921529]\]. As a consequence, patients might suffer from PNF if these assessments are not accurate enough \[[@b37-anntransplant-25-e921529]\]. NMP can now address this issue by *ex vivo* assessment of graft viability before transplantation. During perfusion, parameters like perfusate PH value, lactate level, bile production/components, hepatic artery and portal vein flow, and liver enzyme level in perfusate can be monitored \[[@b11-anntransplant-25-e921529],[@b12-anntransplant-25-e921529]\]. According to the criteria reported by Mergental et al., the perfusion parameters of our 4 donor livers suggest their viability \[[@b38-anntransplant-25-e921529]\]. Importantly, lactate is used as a significant marker to assess the function of liver grafts. During perfusion, our 4 liver grafts presented an interesting phenomenon of lactate clearance. The first liver graft showed a stable level of lactate during the middle of perfusion. The second showed a rapid decrease to below 2.5 mmol/L of lactate clearance. Compared with the situation of lactate in the first liver graft, the lactate level was slightly elevated during the initial perfusion, and lactate clearance rapidly decreased after 1.5 h. The fourth liver showed a gradual decrease of lactate. Finally, all lactate levels were below 2.5 mmol/L at the end of perfusion, meeting the criteria of Mergental et al. \[[@b38-anntransplant-25-e921529]\]. Although the lactate clearance was stable in the first liver graft, the peak post-transplant AST within 7 days was highest among these liver grafts. On the other hand, the presentation of lactate clearance in liver 1 during perfusion indicated that the liver graft parenchymal injury might be more serious because the liver could not clear lactate rapidly in the middle of perfusion. However, the peak post-transplant AST level within 7 days was the lowest, indicating the resuscitation function of NMP. Therefore, lactate clearance as a marker to evaluate liver viability might be incomplete. The rate of lactate clearance measured per unit of liver weight might better indicate viability \[[@b39-anntransplant-25-e921529]\].

During perfusion, perfusate glucose level increased early and stayed at a stable high level. Adding insulin did not affect glucose levels, which is inconsistent with a previous report \[[@b39-anntransplant-25-e921529]\]. Another group showed that bile pH values \>7.5 are a better indicator of healthy cholangiocytes \[[@b13-anntransplant-25-e921529]\]. In all the 4 donor livers, the bile PH values were \>7.5 at the end of perfusion. The glucose levels in bile of liver 1 indicated severe warm ischemia injury before perfusion, and the decreasing trend explained the recovery of cholangiocytes. Glucose levels in bile of the other livers were very low during perfusion. These results suggest that cholangiocytes secreted bicarbonate, resulting in an alkalotic pH, and resorbed the glucose in bile \[[@b35-anntransplant-25-e921529]\]. In addition, bile production is used as a marker of good liver function. The 4 donor livers showed differences in bile production. Nasralla et al. showed that although 18 livers produced minimal bile during perfusion, all presented with good post-transplant liver function, and there was no association between bile production and post-transplant liver function \[[@b13-anntransplant-25-e921529]\].

In liver transplantation, PRS is a common complication of transient hemodynamic changes occurring after liver graft reperfusion. According to the definition by Hilmi et al. \[[@b40-anntransplant-25-e921529]\], 1 case had PRS in this study. Studies have showed that, compared to static cold storage (SCS), NMP can reduce the incidence of PRS. In a study by Angelico et al. \[[@b41-anntransplant-25-e921529]\], 6 patients receiving grafts with NMP had lower incidence of PRS (0% versus 16.7%) compared to 12 matched controls preserved by SCS. Nasralla et al. also showed a significant reduction in PRS rate (12.4% versus 33%, p\<0.001) in the NMP group versus the SCS group \[[@b13-anntransplant-25-e921529]\]. However, Watson et al. found that high oxygen tension in the perfusate during NMP can also lead to PRS \[[@b42-anntransplant-25-e921529]\]. In their study, in the first 6 cases, 5 cases experienced PRS when the mean PaO~2~ was between 621 and 671 mmHg. In contrast, PRS did not occur in the subsequent 6 cases when the level of PaO~2~ was reduced to 153--187 mmHg. Therefore, in our study, the target PaO~2~ level of 200 mmHg might be still too high for the liver graft. However, the optimal PaO~2~ level is unknown.

Our study has some limitations. The number of cases was small, which prevented us from forming strong conclusions. The UK DCD risk scores of cases 1, 2, and 3 were 7, 5, and 4, respectively. The ECD livers were not so severe. This is our preliminary attempt to use NMP to preserve donor livers in China. For the patient safety, we did not try NMP in more severe ECD livers in the beginning. Another limitation is the short follow-up of the patients after transplantation. These limitations need to be addressed in future studies.

Conclusions
===========

This study is the first attempt to use NMP in liver transplantation in China. NMP is feasible as a preservation technique for assessment of ECD livers. Because there are many more DCD and DBCD donors in China, this novel preservation method might provide a valuable strategy to expand the organ pool and improve transplant outcomes.
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![Graft appearance before and during normothermic machine perfusion.](anntransplant-25-e921529-g001){#f1-anntransplant-25-e921529}

![Perfusion parameters and markers of viability assessment during normothermic machine perfusion. (**A, B**) Change of vascular flow during perfusion. (**C**) pH in perfusate. At the beginning of perfusion, pH was low and then rose to normal levels gradually. (**D**) Glucose level in perfusate. During perfusion, liver 1 and liver 4 presented a high level of glucose, while liver 2 and liver 3 demonstrated a relatively normal level. During perfusion, in all grafts, the glucose in perfusate remained stable. (**E**) Lactate clearance during perfusion. All livers showed active condition. At the end of perfusion, perfusate lactate levels dropped below 2.5 mmol/L.](anntransplant-25-e921529-g002){#f2-anntransplant-25-e921529}

![Bile production and results of bile gas analysis during normothermic machine perfusion. (**A--C**) show pH values, HCO~3~^−^, and glucose levels in the bile every hour. (**D**) Bile production during perfusion. (**E**) Centrifuge tubes containing bile from liver 3. The bile production was increasing and the color of bile gradually turned darker.](anntransplant-25-e921529-g003){#f3-anntransplant-25-e921529}

![Liver biopsies with hematoxylin and eosin staining before and after normothermic machine perfusion and after reperfusion. (**A, B**) Shows the livers were well-preserved after perfusion, and the microscopic architecture was little changed.](anntransplant-25-e921529-g004){#f4-anntransplant-25-e921529}

![Presentation of post-transplant liver function from 4 recipients. (**A, B**) show the post-transplant transaminase release after machine perfusion. In all recipients, ALT and AST recovered to normal within the first month. (**C--E**) Demonstrate the change of Tbil and ALP, GGT as markers of bile duct damage after transplantation. (**F**) Recovery of INR as marker of liver coagulation function. \* Recipient \#1 had the complication of anastomotic stenosis post-transplant follow-up 90 days, resulting in abnormal elevation of transaminase, Tbil, ALP, and GGT. ALT -- alanine transaminase; AST -- aspartate transaminase; Tbil -- total bilirubin; GGT -- gamma-glutamyl transferase; ALP -- alkaline phosphatase; INR -- international normalized ratio.](anntransplant-25-e921529-g005){#f5-anntransplant-25-e921529}

###### 

The characteristics of donors and recipients.

  Characteristic                      Case 1                                                                       Case 2                    Case 3                    Case 4
  ----------------------------------- ---------------------------------------------------------------------------- ------------------------- ------------------------- -------------
  **Donor**                                                                                                                                                            
  Age, y                              22                                                                           20                        26                        19
  Sex                                 Female                                                                       Male                      Male                      Female
  Blood type                          B                                                                            O                         AB                        O
  BMI                                 19.53                                                                        21.22                     17.86                     20.81
  Cause of brain injury               Cerebral ischemia                                                            Intracranial hemorrhage   Intracranial hemorrhage   Head trauma
  HBV                                 (−)                                                                          (−)                       (−)                       (−)
  Na (mmol/L)                         155                                                                          173.3                     134                       148
  ALT (U/L)                           11                                                                           36.9                      16.8                      79
  AST (U/L)                           33                                                                           94.4                      27.1                      239
  TBiL (umol/L)                       8.8                                                                          8.9                       27.6                      141.5
  DBD/DCD                             DCD                                                                          DCD                       DCD                       DBD
  WIT (min)                           22                                                                           10                        6                         0
  CIT (min)                           638                                                                          536                       423                       334
  NMP time (min)                      260                                                                          260                       380                       360
  **Recipient**                                                                                                                                                        
  Age, y                              31                                                                           63                        58                        56
  Sex                                 M                                                                            M                         F                         M
  HBV                                 (+)                                                                          (+)                       (+)                       (+)
  MELD                                39                                                                           9                         40                        14
  Reason for transplantation          ALF                                                                          Cirrhosis                 Cirrhosis                 Cirrhosis
  Operation duration (min)            365                                                                          350                       375                       405
  Anhepatic phase (min)               31                                                                           25                        38                        37
  Total blood loss (mL)               3000                                                                         200                       500                       3000
  Blood transfusion (mL)              1200                                                                         0                         0                         1600
  Post-transplantation complication   Biliary stricture[\*](#tfn1-anntransplant-25-e921529){ref-type="table-fn"}   EAD                       NA                        NA
  ICU stay (h)                        85                                                                           36                        60                        23
  Hospital stay (day)                 29                                                                           26                        17                        26

Biliary anastomosis stricture.

BMI -- body mass index; HBV -- hepatitis B virus; DBD -- donor after brain death; DCD -- donor after cardiac death; WIT -- warm ischemia time; ALT -- alanine transaminase; AST -- aspartate aminotransferase; TBIL -- total bilirubin; CIT -- cold ischemia time; NMP -- nomorthermic machine perfusion; MELD -- model for end-stage liver disease; ALF -- acute liver failure; EAD -- early allograft dysfunction; NA -- not available.
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